-
Over 2 billion "magic medicine" fell!
Time of Update: 2021-11-14
According to data from Mi Nei. com, due to the impact of centralized procurement, the sales of anti-gout preparations, which have continued to expand in the market, have fallen for the first time in recent years .
-
Shamrock Bio's Hong Kong stock IPO, with a market value of 15.5 billion Hong Kong dollars
Time of Update: 2021-11-14
Among them, Hillhouse Capital exclusively invested in Shamrock Bio's B2 round of 172 million yuan in financing.
Hillhouse Capital and Temasek led the investment of Shamrock Bio's $230 million in Series C financing in March this year .
-
R&D ADC vs PDC——Inventory of current status of ADC-PDC drug R&D at home and abroad
Time of Update: 2021-11-14
The FDA accelerated the approval of Pepaxto combined with dexamethasone for the treatment of patients with relapsed refractory multiple myeloma (RRMM), based on the results of a pivotal phase II clinical trial (HORIZON), these patients have previously received at least four previous therapies, including proteases Body inhibitors, immunomodulators, monoclonal antibodies targeting CD38 .
-
Notice of the Office of the National Medical Security Administration on Doing a Good Job in Continuing Work after the Expiry of the National Organizational Drug Centralized Purchase Agreement
Time of Update: 2021-11-14
The medical insurance bureaus of all provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps: In order to implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Drug Centralized and Volume Procurement" (Guobanfa [2021] No.
-
Notice on Public Solicitation of ICH E14 and Q&A and Q3C (R8) Guiding Principles Implementation Suggestions
Time of Update: 2021-11-14
In order to do a good job in the implementation of the ICH guidelines, our center has drafted the ICH "E14 and Q&A: Non-antiarrhythmic drugs-induced QT/QTc interval prolongation and potential arrhythmogenic effects of clinical evaluation and Q&A documents" and "Q3C (R8) ): Impurities: Residual Solvents" Guiding Principles Transformation and Implementation Suggestions are now open for comments .
-
What can we learn from the collaborative innovation development results of the biomedical industry in the Chengdu-Chongqing Economic Circle
Time of Update: 2021-11-14
On October 20, 2021, the Central Committee of the Communist Party of China and the State Council issued the "Plan for the Construction of the Chengdu-Chongqing Double City Economic Circle", proposing to coordinate the development of biomedicine, medical equipment, and modern Chinese medicine industries to jointly build a large western health industry base .
-
October 2021 Global Healthcare Investment and Financing Monthly Report: The total amount of digital health financing far exceeds that of biomedicine, and both the number and total amount of medical device financing have dropped
Time of Update: 2021-11-14
788 billion US dollars, an increase of about 32% from the previous month There were 106 financing projects in the domestic medical and health sector, with a total financing of approximately US$2.
-
250 billion yuan saved in 3 years!
Time of Update: 2021-11-14
Taking the data of 25 selected varieties of 4+7 centralized procurement as an example, in 2019, the total number of times of drug use in designated medical institutions under the same generic name and dosage form reached 152 million times, a year-on-year increase of 23% compared with 2018 .
-
Notice on Publicly Soliciting Opinions on the "Regulations for the Suspension and Resumption of Review Timings in the Drug Review Process of the State Drug Administration (Trial)"
Time of Update: 2021-11-14
27 of the State Administration for Market Regulation), our center organized the drafting of the "Regulations for the Suspension and Resumption of Review Timing in the Process of Drug Review by the State Drug Administration (Trial)" , Now the center website is publicized to listen to opinions and suggestions from all walks of life .
-
Zai Lab has introduced over US$300 million, is it not too late to establish a KRAS inhibitor?
Time of Update: 2021-11-14
Figure 2 China's leading institutions for KRAS related patents Data source: The opening report of the 6th China Pharmaceutical Innovation and Investment Conference for Listed Companies by Hu Yuanjia, "Excavating Patent Data to Help New Drug Research and Development" At present, there are 11 KRAS inhibitors that have reached the clinical stage, of which 7 have been in clinical trials.
-
Notice of the Comprehensive Department of the State Food and Drug Administration on the activation of the API production and supply information collection module
Time of Update: 2021-11-14
Operation manual for the monitoring end of the API production and supply information collection module Comprehensive Department of State Food and Drug Administration November 1, 2021
-
NEJM Phase 3 trial data: What is the long-term protection of the new crown vaccine against the Delta strain?
Time of Update: 2021-11-14
The analysis of the data of nearly 25,000 people in the phase 3 trial of the mRNA-1273 new crown vaccine shows that the Delta virus of the newly vaccinated (December 2020-April 2021) population compared to the earliest vaccinated (July-December 2020) population The morbidity and severe disease rate after infection of the strain is lower .
-
Decei Pharma announced that the Phase Ib clinical trial application of ATG-008 combined with ATG-010 was approved in China for the treatment of diffuse large B-cell lymphoma
Time of Update: 2021-11-14
The National Medical Products Administration (NMPA) has approved ATG-008 (onatasertib) combined with ATG-010 (selinexor) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (rrDLBCL) for dose exploration and safety open phase Ib Research The trial is in China with Sun Yat-sen University Cancer Center as the lead research center, and it is planned to be carried out in 10 domestic research centers .
-
Researchers report the reliability of Pfizer's new crown vaccine trial data, and the effectiveness of FDA clinical supervision is questioned
Time of Update: 2021-11-14
The article reported an internal whistleblower's revelation of the bad practices of the contract research company that helped conduct Pfizer's key new crown vaccine trial , Which has raised concerns about the reliability of data and the effectiveness of FDA supervision .
-
FDA grants Pfizer/BioNTech's new crown vaccine for emergency use authorization for children aged 5 to 11 years
Time of Update: 2021-11-14
On October 29, the US Food and Drug Administration (the US Food and Drug Administration, FDA) granted Pfizer/BioNTech the emergency use authorization for the new crown vaccine for children aged 5 to 11 .
-
The stock price of pharmaceutical companies has broken frequently. Who will pay for the Me Too project for the IPO?
Time of Update: 2021-11-14
Table 1 New shares broken on the first day of listing in OctoberTable 1 New shares broken on the first day of listing in October Data source: Straight Flush The share price break rate of new drug research and development companies on the science and technology board is gradually increasing Coincidentally, some of the new drug R&D companies listed on the Science and Technology Innovation Board in 2019 have gradually broken or even broken .
-
27 years of game, three rounds of reform experiment of China's medical payment
Time of Update: 2021-11-14
The payment method has always been regarded as a lever between medical institutions, medical insurance and patients, guiding hospitals to actively improve service quality and reasonably control service costs .
-
Thirty years of ups and downs in the "past and present" of stem cell therapy
Time of Update: 2021-11-14
Recently, the world’s top pharmaceutical company Vertex released the latest clinical trial data on the treatment of type I diabetes with VX-880 allogeneic stem cell therapy.
com/s?id=1618737996109128231&wfr=spider&for=pc[2]https://baijiahao.
-
Increased by 9.77%! 2021H1 China's public medical institutions’ terminal drug sales amounted to 617.4 billion yuan, achieving restorative growth
Time of Update: 2021-11-14
In the first half of 2021, as the domestic epidemic gradually eases, China's economy continues to recover steadily, market demand continues to rebound, and economic development is steadily improving
-
"Puhuibao" flowers bloom!
Time of Update: 2021-11-14
Pratt & Whitney has attracted much attention due to its low threshold, high insurance coverage, and price benefits for providing compensation for patients suffering from major diseases and large medical expenses .
